Clinical Research Directory
Browse clinical research sites, groups, and studies.
Impact of Androgen Signaling on the Composition of the Immune Microenvironment in Glioblastomas
Sponsor: Assistance Publique - Hôpitaux de Paris
Summary
Glioblastoma (GBM) is the most common and most aggressive primary brain cancer in adults. GBM is more common in men than in women, with a male-to-female ratio of 1.6. Furthermore, being male is associated with a poorer prognosis. These data suggest that sex and/or sexual hormones and more specifically androgens may play a role in the initiation, the growth, and the resistance to treatments of GBM.
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2026-04-01
Completion Date
2030-04-01
Last Updated
2026-03-16
Healthy Volunteers
No
Conditions
Interventions
blood sampling
Additional blood samples (in addition to those taken as part of treatment) will be taken from patients at T1 (before any medical treatment) and at T2 (one month after the end of concomitant chemoradiotherapy). These samples, totaling 6 to 8 mL, will be taken between 9 a.m. and 11 a.m. (this time slot allows patients to normalize their circadian rhythm)
saliva sampling
During these same visits at T1 and T2, a saliva sample will be collected using Salivette® Cortisol saliva collection devices (UGAP ref.: 2745674)
stool sampling
During these same visits at T1 and T2, a stool sample will be collected by the patient using the kit (Stool Sample Collection Kit with Stool Catcher, Canvax)
Tumor sampling
At the time of surgery performed as part of treatment (before T1), tumor tissue from the surgical waste will be collected.
Locations (1)
Neuro-oncology department, Pitié Salpêtrière hospital
Paris, France